Title:
Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対する特異性を有する抗体及び診断目的のためのその使用
Document Type and Number:
Japanese Patent JP7455108
Kind Code:
B2
Abstract:
Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a quasi-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 10 to 23 of SEQ ID NO: 1.
Inventors:
Cockrel-Diploy, Lorance
Montpellier, Claire
Dubuisson, Jean
Montpellier, Claire
Dubuisson, Jean
Application Number:
JP2021500401A
Publication Date:
March 25, 2024
Filing Date:
July 09, 2019
Export Citation:
Assignee:
Ansitu National de la Sant'E de la Cherche Medical
Anstitu pasteur reel
Anstitu pasteur reel
International Classes:
C07K16/10; C12M1/34; G01N33/576
Domestic Patent References:
| JP8509692A | ||||
| JP2013226136A |
Other References:
C. Montpellier, et al.,Gastroenterology,2018年,Vol.154,p.211-223
Attorney, Agent or Firm:
Patent Attorney Corporation Tsukuni